INTRODUCTION
============

The vascular endothelium consists of a layer of endothelial cells in the inner surface of blood vessels and is a crucial barrier between the blood and tissue environments. The vascular endothelium plays a pivotal role in vascular permeability, maintenance of vascular tone and pressure, platelet aggregation, and thrombosis ([@ref39]). Endothelial cells can be easily damaged by various factors, such as inflammatory cytokines and reactive oxygen species (ROS), which cause endothelial dysfunction that, in turn, initiate early processes of vascular diseases, including atherosclerosis, hypertension, and peripheral venous disease ([@ref25]; [@ref8]).

In particular, oxidative stress caused by ROS is a critical factor in the pathogenesis of vascular diseases. In the endothelium, ROS are produced by diverse metabolic enzymes, such as reduced nicotinamide adenine dinucleotide phosphate oxidase, lipoxygenase, and xanthine oxidase ([@ref55]; [@ref2]). Overproduction of ROS in vascular lesions disrupts the balance between cell survival and cell death signaling pathways, peroxidizes membrane lipids, and triggers the production of several inflammatory mediators ([@ref28]; [@ref63]). As a result, endothelial permeability is increased, and inflammatory cells, such as monocytes, migrate to the endangium by binding to cell adhesion molecules, which is important during the development of vascular diseases ([@ref6]). Therefore, antioxidant agents that attenuate the generation of ROS may have therapeutic applications in reducing endothelial cell damage. For example, vitamin E supplementation has been shown to reduce free radical production and vascular injury progression *in vivo* ([@ref23]). In addition, regular ingestion of fruit and vegetables can diminish the risk of vascular diseases since many plant constituents contain a phenolic group in their chemical structure, such as flavonoids and phenolic acids, which exhibit antioxidant activity ([@ref26]; [@ref37]; [@ref58]). Therefore, studies have been actively conducted to identify plants that can protect endothelial cells against oxidative stress. For instance, [@ref9] showed that lemongrass polyphenols suppresses oxidative damage in human endothelial cells. Additionally, [@ref57] showed that the *Polygonum orientale* flower extract can protect human umbilical vein endothelial cells (HUVECs) from hydrogen peroxide (H~2~O~2~)-triggered oxidative damage by enhancing the activity of antioxidant enzymes, such as superoxide dismutase (SOD) and catalase (CAT).

H~2~O~2~, one of the major components of ROS, can damage the endothelium ([@ref36]). H~2~O~2~ has been widely used to induce oxidative stress in vascular endothelial cells because it can easily penetrate their membranes ([@ref14]). Thus, stimulation with H~2~O~2~ is a good strategy for investigating vascular endothelial damage.

*Vitis vinifera* L. is a woody perennial vine plant that usually climbs via tendrils. It is native to Asia Minor, from which it spread to other continents, including Europe ([@ref42]). The fruit of *V. vinifera* L. is mainly used as food, whereas its seeds and leaves are used as herbal medicine and food supplements. The leaves have a long history of being used as a folk medicine to treat diarrhea, vomiting, wounds, and bleeding in Ayurvedic medicine ([@ref31]; [@ref43]). In previous studies, extracts of *V. vinifera* L. leaves have shown a hepatoprotective effect against carbon tetrachloride-induced acute liver damage and alcohol- induced oxidative damage in rats ([@ref31]; [@ref42]; [@ref46]; [@ref43]). Recently, [@ref50] also showed that *V. vinifera* L. leaf extracts (VE) with the highest quercetin 3-glucuronide content among phenols inhibits inflammation in human keratinocytes. In particular, the leaf extracts were shown to contain higher levels of total phenols and proanthocyanidins than stalk and marc extracts, and exhibited a greater effect on reducing intracellular ROS induced by H~2~O~2~ in human dermal fibroblasts ([@ref47]). Despite these previous studies on *V. vinifera* L. leaf, its role in protecting vascular endothelial cells against oxidative damage has not previously been reported.

*Centella asiatica* is a traditional medicinal plant found in various tropical regions, including Asia, South Africa, and the Middle East Africa. *C. asiatica* has long been used as a traditional medicine for wound healing and scar management in Asia ([@ref18]). It also has various biological effects, such as anti-inflammatory, antioxidant, neuroprotective, and hepatoprotective activities ([@ref53]; [@ref64]; [@ref44]; [@ref66]). Recently, the major triterpenoid compounds of *C. asiatica*, asiaticoside, and asiatic acid were shown to inhibit endothelial hyperpermeability triggered by tumor necrosis factor-α (TNF-α) in human aortic endothelial cells ([@ref20]; [@ref18]). Moreover, madecassoside, another triterpenoid in *C. asiatica*, has been shown to inhibit apoptosis of HUVECs following exposure to H~2~O~2~-induced oxidative stress ([@ref4]). Therefore, *C. asiatica* might protect vascular endothelial cells against oxidative stress.

Recently, the synergistic effects of phytochemicals have received increasing interest, with the aim of achieving more effective therapies for treating various diseases, including vascular diseases. Because both *V. vinifera* L. leaf and *C. asiatica* contain various active compounds, such as flavonoids, anthocyanidins, and triterpenoids, that exhibit anti-inflammatory and antioxidant effects, the combination of these two extracts may have a synergistic effect. Here, we investigated whether the standardized herbal combination of *V. vinifera* L. leaf extract and *C. asiatica* extract is effective in protecting vascular endothelial cells against oxidative stress induced by H~2~O~2~.

MATERIALS AND METHODS
=====================

Chemicals and reagents
----------------------

Acetonitrile and high-performance liquid chromatography (HPLC) grade water were purchased from J.T. Baker Chemical Co. (Phillipsburg, NJ, USA). H~2~O~2~ and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Oxygen radical antioxidant capacity (ORAC) activity assay kit and intracellular ROS assay kits were purchased from Cell Biolabs Inc. (San Diego, CA, USA) and Abcam (Cambridge, UK), respectively. The total nitric oxide (NO) assay kit and human vascular endothelial-cadherin (VE-cadherin) enzyme-linked immunosorbent assay (ELISA) kit were purchased from R&D Systems (Minneapolis, MN, USA). The *in vitro* vascular permeability assay kit was purchased from Millipore (Bedford, MA, USA).

*V. vinifera* L. leaf and *C. asiatica* extracts preparation
------------------------------------------------------------

Dried leaves of *V. vinifera* L. and *C. asiatica* were purchased from an herbal market (Danyang, China). The ethanol extract of *V. vinifera* L. leaf (VE) was obtained by macerating 200 g of dried leaves with 40% ethanol for 4 h. The spent plant material was extracted again using the same solvent. After filtering the extract using Advantec filter paper No. 1 (Advantec, Japan), the combined extracts were concentrated and dried. The ethanol extract of *C. asiatica* (CE) was obtained by macerating 200 g of dried leaves with 70% ethanol for 3 h and was refluxed twice more. Obtained extracts were combined, filtered, concentrated, and the residual extract was dried. The *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) was prepared by mixing dried powders of VE and CE at a ratio of 3:1 to produce standardized VCEC.

Calibration of the HPLC method
------------------------------

The analysis of quercetin 3-*O*-β-D-glucuronide (quercetin 3-glucuronide) and asiaticoside was performed with reference to methods previously published ([@ref52]; [@ref48]; [@ref3]; [@ref12]). Approximately 3.0 mg each of quercetin 3-glucuronide and asiaticoside standard compounds were placed in a 3-mL volumetric flask and dissolved with methanol. Further calibration concentrations were prepared by diluting a standard solution with methanol. The detector response was linear within the range of concentrations injected (quercetin 3-glucuronide: 5∼ 80 μg/mL, asiaticoside: 25∼400 μg/mL). The calibration data are listed in [Table 1](#T1){ref-type="table"}.

HPLC analysis of quercetin 3-glucuronide and asiaticoside
---------------------------------------------------------

An Agilent HPLC 1200 series system (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with a quaternary pump, autosampler, and photodiode array detector with a Phenomenex^Ⓡ^ Luna C18 column (250×4.6 mm, 5 mm) was used for HPLC analysis (Phenomenex Inc., Torrance, CA, USA). For the analysis of quercetin 3-glucuronide, we eluted the extract with solvent A (acetonitrile) and solvent B (1% formic acid in water) in a gradient elution at a flow rate of 0.7 mL/min, as follows: 0∼ 22 min, 83% B; 22∼28 min, 83∼20% B; 28∼33 min, 20% B; 33∼35 min, 20∼83% B; and 35∼40 min, 83% B. The column temperature was kept at 25°C, and the absorbance was detected at 360 nm. For analysis of asiaticoside, we eluted with solvent A (acetonitrile) and solvent B (0.3% phosphoric acid in water) in a gradient elution at a flow rate of 1 mL/min, as follows: 0∼5 min, 75% B; 5∼20 min, 75∼65% B; 20∼25 min, 65∼25% B; 25∼30 min, 25% B; 30∼32 min, 25∼75% B; and 32∼40 min, 75% B. The column temperature was kept at 35°C, and the detection wavelength was 205 nm. The injection volume of all samples was 10 μL.

ORAC assay
----------

ORAC was measured using the OxiSelect^TM^ ORAC assay kit following the manufacturer's instructions. Fluorescence was detected at 480 nm \[excitation (ex)\] and 520 nm \[emission (em)\] every 3 min for a total of 180 min using a Victor 3 multilabel plate reader (PerkinElmer, Inc., Norwalk, CT, USA). The area under the curve of each sample was calculated and compared with the Trolox^TM^ (2.5∼50 μM) antioxidant standard curve. ORAC values were presented in μM Trolox equivalents per g of VE, CE, and VCEC.

Cell culture
------------

HUVECs were purchased from Lonza (Baltimore, MD, USA). Cells were cultured in M200 (Gibco, Grand Island, NY, USA) supplemented with an low serum growth supplement kit (Gibco) and incubated at 37°C in a humidified atmosphere with 5% CO~2~. The culture medium was replaced every 2 days until cells were confluent. All experiments were performed using cells at passages 3∼6.

Cell viability
--------------

To measure cell viability, MTT assays were used. MTT assays are based on the ability of living cells to metabolize a water-soluble tetrazolium salt into a water-insoluble formazan crystal. HUVECs (2×10^5^ cells/mL) were cultured for 24 h in a 96-well plate and then treated with various concentrations of VE, CE, and VCEC for 24 h. The medium was discarded, and then 5 μg/mL MTT solution was added to each well. After incubation for 3 h at 37°C, the MTT solution was discarded, and 100 μL of dimethyl sulfoxide was added to each well to solubilize formazan. The absorbance was detected at 540 nm with a Victor 3 multilabel plate reader (PerkinElmer, Inc.).

Intracellular ROS production
----------------------------

Intracellular ROS production was measured using the cell-permeable reagent 2',7'-dichlorofluorescein (DCF)- diacetate (DA) ([@ref38]). HUVECs (3×10^5^ cells/mL) were cultured in a 96-well black plate for 24 h and then treated with various concentrations of VE, CE, and VCEC for 30 min, followed by 500 μM H~2~O~2~ for 4 h. Cells were washed with assay buffer and then incubated with 25 μM 2',7'-dichlorodihydrofluorescein (DCFH)-DA in assay buffer supplemented with 10% fetal bovine serum for 45 min at 37°C. ROS was measured by detecting DCF fluorescence (ex: 485 nm, em: 535 nm) using a Victor 3 multilabel plate reader (PerkinElmer, Inc.).

NO release
----------

HUVECs (2×10^5^ cells/mL) were cultured in a 96-well plate for 24 h. HUVECs were then treated with 37.5 mg/ mL of VE, 12.5 μg/mL of CE, and 50 μg/mL of VCEC for 30 min, followed by 500 μM H~2~O~2~ for 4 h. The amount of NO in culture supernatants was spectrophotometrically analyzed by evaluating the accumulation of nitrate and nitrite using a colorimetric NO assay kit according to the manufacturer's instructions. The absorbance was detected at 540 nm using a Victor 3 multilabel plate reader (PerkinElmer, Inc.).

Transendothelial electrical resistance (TEER) assay
---------------------------------------------------

The TEER across the HUVEC monolayer was measured using a Millicell-ERS ohmmeter (Millipore) ([@ref30]). HUVECs (0.5 mL) were seeded in the inserts of transwell plates (12-well type, 4×10^5^ cells/well), and 1.5 mL of culture medium was added to the receiver plate wells. The culture medium was changed every 2 days. Once cells formed a tight monolayer, cells were treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, and 50 mg/ mL of VCEC for 30 min, followed by 500 μM H~2~O~2~ for 4 h. TEER ( Ω·cm^2^) was determined by multiplying the measured electrical resistance (Ω) by the surface area of the membrane (cm^2^).

Vascular permeability assay
---------------------------

Vascular permeability was measured using an *in vitro* vascular permeability assay kit according to the manufacturer's instructions. Briefly, 0.2 mL of HUVECs were seeded on the inserts of transwell plates (24-well type, 2×10^5^ cells/well), and 0.5 mL of culture medium were added to the receiver plate wells. The culture medium was changed every 2 days, and cells were incubated until a monolayer was formed. Cells were treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, and 50 μg/mL of VCEC for 30 min, followed by 500 μM H~2~O~2~ for 4 h. Then, fluorescein isothiocyanate (FITC)-dextran was added to the inserts and allowed to penetrate the monolayers for 20 min. A total of 0.1 mL of the media in each receiver plate well was transferred into a black 96-well plate. The fluorescence intensity was detected at 480 nm (ex) and 520 nm (em) using a Victor 3 multilabel plate reader (PerkinElmer, Inc.)

VE-cadherin expression
----------------------

HUVECs (3×10^6^ cells/mL) were cultured in a 12-well plate for 24 h and then treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, and 50 μg/mL of VCEC for 30 min, followed by 500 μM H~2~O~2~ for 4 h. The cells were lysed in radioimmunoprecipitation assay buffer containing a protease inhibitor cocktail (ATTO, Tokyo, Japan). The levels of VE-cadherin in the cell lysates were detected using a human VE-cadherin ELISA kit following the manufacturer's instructions.

Statistical analysis
--------------------

The data are expressed as mean±standard deviation (SD). All experiments were performed in triplicate and repeated three times. Statistical significance was analyzed by Student's *t*-test, and *P*\<0.05 was considered significant. Statistical tests were conducted using the SPSS standard version 26 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

HPLC analysis of VCEC
---------------------

Based on the absorption profile and retention time, quercetin 3-glucuronide and asiaticoside were identified as the major compounds in VCEC. [Fig. 1A](#F1){ref-type="fig"} and [2A](#F2){ref-type="fig"} show the HPLC chromatograms of quercetin 3-glucuronide and asiaticoside standards for peak comparison with the chromatogram of VE ([Fig. 1B](#F1){ref-type="fig"} and [2B](#F2){ref-type="fig"}), CE ([Fig. 1C](#F1){ref-type="fig"} and [2C](#F2){ref-type="fig"}), and VCEC ([Fig. 1D](#F1){ref-type="fig"} and [2D](#F2){ref-type="fig"}). According to the HPLC chromatograms, quercetin 3-glucuronide was detected at 360 nm with a retention time of 26.9 min, and asiaticoside was detected at 205 nm with a retention time of 14.9 min. The results confirmed that VE and VCEC contained 11.4±0.16 and 8.5±0.12 mg/g of quercetin 3-glucuronide, respectively, and CE and VCEC contained 95.6±0.22 and 24.9±0.17 mg/g of asiaticoside, respectively ([Table 2](#T2){ref-type="table"}).

Antioxidant activity of VCEC
----------------------------

To confirm the antioxidant activity of VCEC and individual extracts of VE and CE, ORAC assays were conducted using Trolox^TM^ as the standard. VE and CE showed similar antioxidant activities ([Fig. 3](#F3){ref-type="fig"}). Remarkably, VCEC demonstrated ∼1.7-fold higher antioxidant activity than VE or CE alone (*P*\<0.01), suggesting that VE and CE have a synergistic effect on antioxidant activity.

Effect on HUVEC viability
-------------------------

We investigated the effect of VCEC on the vascular endothelium using HUVECs, a classical model system for studying endothelial function. We treated cells with VE and CE at the same concentration as contained in VCEC to evaluate whether VC and CE show synergistic effects on endothelial function compared with each compound alone. First, we examined the effects of VE, CE, and VCEC on HUVEC viability to investigate potential cell cytotoxicity. Concentrations of up to 37.5 μg/mL of VE, 12.5 μg/mL of CE, and 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) did not affect the viability of HUVECs, as determined by the MTT viability assays ([Fig. 4](#F4){ref-type="fig"}).

Effect on intracellular ROS production
--------------------------------------

To examine the effect of VCEC on ROS production, we measured intracellular ROS by using a DCFH-DA fluorescent probe. The fluorescence intensity of cells exposed to H~2~O~2~ alone dramatically increased to ∼7.6-fold compared with the control group (*P*\<0.001); however, pretreatment with VCEC (6.25, 12.5, 25, or 50 μg/mL) significantly attenuated the increase in fluorescence intensity induced by H~2~O~2~ (*P*\<0.001) in a dose-dependent manner ([Fig. 5](#F5){ref-type="fig"}). In particular, 25 and 50 μg/mL of VCEC decreased the amount of ROS to a level similar to that of the control group. Pretreatment with VE (4.69, 9.38, 18.75, or 37.5 μg/mL) or CE (3.12, 6.25, or 12.5 μg/mL) also significantly inhibited ROS production, but pretreatment with VCEC induced a greater inhibitory effect compared with that for VE or CE alone.

Effect on NO level
------------------

To examine the effect of VCEC on NO levels, we measured the total NO in the culture supernatants. Exposure to H~2~O~2~ for 4 h considerably reduced NO release to 86.5 ±3.7% compared with the control group (*P*\<0.05) ([Fig. 6](#F6){ref-type="fig"}). Pretreatment of cells with 37.5 μg/mL of VE and 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) significantly suppressed the decrease in NO release induced by exposure to H~2~O~2~, whereas NO release was not impacted by 12.5 μg/mL of CE.

Effect on HUVEC TEER
--------------------

We further estimated the ability of VCEC to preserve the endothelial monolayer barrier function by using TEER measurements and permeability assays. First, TEER in the HUVEC monolayer was measured using a Millicell- ERS ohmmeter during H~2~O~2~ exposure. H~2~O~2~ substantially decreased TEER to 61±3% compared with the control group ([Fig. 7](#F7){ref-type="fig"}), indicative of damage to the endothelial barrier. Pretreatment of the HUVEC monolayers with 37.5 μg/mL of VE and 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) for 30 min prior to H~2~O~2~ exposure protected the monolayer integrity against H~2~O~2~-induced endothelial barrier dysfunction, whereas 12.5 mg/ mL CE was ineffective. In addition, treatment of the monolayer with VCEC significantly attenuated the reduction in TEER to a greater extent than treatment with VE alone.

Effect on HUVEC monolayer permeability
--------------------------------------

In addition to measuring TEER, permeability assays were conducted to investigate the integrity of the HUVEC monolayer. We used an *in vitro* vascular permeability assay kit to measure the accumulation of FITC-conjugated dextran passing through the HUVEC monolayer. H~2~O~2~ significantly increased permeability to 218.3±16.9% compared with the control group, and pretreatment with 37.5 μg/mL of VE, 12.5 μg/mL of CE, and 50 μg/mL VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) prominently abolished the H~2~O~2~-induced hyperpermeability ([Fig. 8](#F8){ref-type="fig"}). Treatment of the monolayer with VCEC showed a significantly greater inhibitory effect that treatment with VE or CE alone. To confirm the unexpected synergistic effect of VE and CE on HUVEC permeability, we used Colby's equation ([@ref11]) to determine the benefit of combining VE and CE. This equation has been used to evaluate the benefit of other herbal extract mixtures ([@ref60]). The observed value (77.8%) was greater than the expected hypothetical value (74.8%), indicating the existence of a synergistic effect of the two extracts ([Table 3](#T3){ref-type="table"}).

Effect on VE-cadherin expression
--------------------------------

To elucidate the regulatory mechanism of VCEC on endothelial barrier function, the expression of VE-cadherin, a major component of endothelial adherens junctions, was assessed by ELISA. H~2~O~2~ decreased the expression of VE-cadherin to 77.8% of the control ([Fig. 9](#F9){ref-type="fig"}). However, pretreatment with 37.5 μg/mL of VE, 12.5 μg/mL of CE, and 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) significantly abolished the H~2~O~2~-induced reduction in VE-cadherin expression. In particular, there was a greater inhibitory effect for treatment with VCEC compared with VE or CE alone.

DISCUSSION
==========

Vascular disease, a disorder of the blood vessels, is one of the most prominent chronic diseases, and develops gradually over a long period of time ([@ref17]). Endothelial damage induced by oxidative stress related to obesity, hyperlipidemia, and aging is considered to be an early biomarker in the pathogenesis of several vascular diseases ([@ref45]; [@ref2]). A previous study demonstrated that high levels of oxidative stress are related to a remarkable increase in endothelial cell cytotoxicity ([@ref24]). Therefore, there is now a substantial amount of research being conducted on new antioxidant agents that can reduce the oxidative stress of blood vessels. Recently, [@ref40] showed that scutellarin, a major active compound in *Erigeron breviscapus*, ameliorated hyperlipidemia and oxidative injury in rats fed a high-fat diet. Moreover, [@ref21] showed that *Echinodorus grandiflorus* extracts reduce atherosclerotic lesions in rabbits receiving a cholesterol-rich diet by decreasing lipid and protein oxidation. Thus, the discovery of new antioxidant agents that reduce oxidative stress in the endothelium is a useful strategy for decreasing the risk of vascular disease ([@ref56]).

To develop a new herbal combination, we investigated the synergistic effect of VE and CE on the protection of endothelial cells against oxidative stress. First, we examined the antioxidant activities of VE, CE, and VCEC using ORAC assays. VCEC exhibited a significantly greater antioxidant capacity than VE or CE alone. Generally, the antioxidant activities of herbs are mainly associated with their phenolic and flavonoid compounds ([@ref67]). *V. vinifera* L. leaves contain various flavonoids, such as quercetin 3-glucuronide, quercetin 3-glucoside, kaempferol 3-glucoside, and cyanidin 3-glucoside ([@ref50]). In addition, *C. asiatica* contains a variety of triterpenoids, such as asiaticoside, asiatic acid, madecassoside, and madecassic acid ([@ref22]). Because using different compounds together may affect their properties, mixtures of plants can show synergistic effects. For instance, rosemary and sage extracts exhibit a synergistic effect on antioxidant activity ([@ref29]), and *Salvia miltiorrhiza* and *Dalbergia odorifera* extracts synergistically attenuate rat myocardial ischemia/ reperfusion injury ([@ref41]). Moreover, when we investigated H~2~O~2~-induced intracellular ROS production in HUVECs, pretreatment with VCEC inhibited ROS production to a greater extent than VE or CE alone. As mentioned above, oxidative stress induced by ROS induces endothelial damage via oxidation of the cell membrane, nucleotides, and proteins. Furthermore, ROS can trigger the generation of inflammatory cytokines, such as TNF-a and interleukin-8, as well as cell adhesion molecules, which induce binding of monocytes to endothelial cells ([@ref13]; [@ref59]). Therefore, the inhibitory effect of VCEC on ROS production is critical for protection of the endothelium against oxidative stress.

NO is one of the most critical regulators of endothelial function that is released by endothelial cells. NO is a vasorelaxant that plays a beneficial role in maintaining blood pressure and cardiovascular physiology ([@ref15]). Decreased levels of endothelium-derived NO are associated with pathophysiological modifications that occur in several vascular diseases ([@ref16]). In previous studies, H~2~O~2~ has been shown to inhibit NO production via reducing endothelial NO synthase activity and to increase hyperpermeability of endothelial cells ([@ref7]; [@ref62]). Consistent with this finding, our results showed that H~2~O~2~ significantly reduced NO production in HUVECs. However, preincubation with VCEC significantly attenuated the H~2~O~2~-induced decrease in NO generation to a greater degree than preincubation with VE or CE. These findings suggest that VE may exert a synergistic effect with CE on NO production.

In addition, we evaluated the ability of VCEC to protect the endothelial barrier function of HUVEC monolayers against H~2~O~2~-induced oxidative stress. The endothelial cell monolayer barrier is critical for maintaining vascular homeostasis, and forming a gateway between the vascular lumen and vascular wall ([@ref49]). Various factors can disturb the structure and function of the endothelial barrier and ultimately cause numerous vascular diseases. One of these factors is oxidative stress; during oxidative stress, ROS can induce barrier leakage by upregulating vascular endothelial growth factor (VEGF) and disrupting the integrity of tight junctions, which subsequently increases permeability to macromolecules, fluids, and inflammatory cells ([@ref10]; [@ref65]). In this study, we used TEER measurements and permeability assays to estimate the integrity of the endothelial monolayer in HUVECs. If the integrity of the monolayer is unstable, membrane electrical resistance is low, and paracellular transport of FITC- dextran across the monolayer will increase. Our data indicated that H~2~O~2~ dramatically decreased the TEER value and increased the endothelial permeability of FITC-dextran. This indicates that the decreased TEER value of the monolayer reflects the increase in monolayer permeability. Pretreatment of the HUVEC monolayer with VE, CE, or VCEC substantially inhibited the decrease in TEER value induced by H~2~O~2~; however, inhibition by CE did not reach statistical significance. Furthermore, the increased FITC-dextran permeability stimulated by H~2~O~2~ was significantly reduced by the three treatments, in the following order of magnitude: VCEC\>VE\>CE. In particular, unexpected synergy was observed for VCEC in the permeability assay when calculated by Colby's equation, which has been previously used to determine the benefit of blending other herbal extracts ([@ref61]). This protective effect of VCEC on barrier integrity might be related to its ability to inhibit ROS production and increase NO. Furthermore, VCEC upregulated VE-cadherin in conditions of oxidative stress. VE-cadherin is a major molecule involved in adhesion at endothelial adherens junctions and thus regulates paracellular permeability ([@ref51]). Various inflammatory mediators, including cytokines and oxidative stress, reduce VE-cadherin expression in vascular endothelial cells and, consequently, increase endothelial cell permeability (Alexander et al., 2000; [@ref27]). We showed that VCEC inhibited the decrease in VE-cadherin expression induced by H~2~O~2~. This result suggests that VCEC protects the endothelial barrier function by regulating adhesion molecules. However, other signaling factors may also be associated with the activity of VCEC.

The mitogen-activated protein kinase (MAPK) family of proteins, which includes p38 MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2), and c-Jun-NH~2~-terminal kinase, is known to regulate vascular permeability ([@ref5]). Specifically, it has been reported that H~2~O~2~ triggers an increase in HUVEC solute permeability through disorganizing tight junction proteins, such as occludin and zonula occludens (ZO)-1, via activating ERK1/2 and/or p38 MAPK pathways ([@ref32]; [@ref33]). Additionally, H~2~O~2~ induces vascular permeability by upregulating VEGF, a vascular permeability factor and an endothelial cell-specific mitogen ([@ref10]; [@ref34]). In recent studies, VE has been shown to counteract the release of VEGF induced by H~2~O~2~ in human keratinocytes, and stem extracts have been shown to reduces levels of VEGF in human endothelial cells ([@ref54]; [@ref50]). In another study, the major compound of VE, quercetin 3-glucuronide, was shown to inhibit ROS generation and lipid peroxidation by increasing the activities of antioxidant enzymes, such as SOD and CAT, by upregulating heme oxygenase-1 via the transcription factors nuclear factor E2-related factor 2 and activator protein-1 ([@ref35]). In the case of *C. asiatica*, the major active compounds asiaticoside and asiatic acid protect against TNF-a-induced endothelial barrier dysfunction by abrogating the structural reorganization of occludin, ZO- 1, and adherens junction proteins, such as VE-cadherin and β-catenin ([@ref20]; [@ref19]). Furthermore, madecassoside, another active constituent, inhibits p38 MAPK activity induced by H~2~O~2~ in HUVECs ([@ref4]). Given these findings, it is possible that various compounds contained in the standardized blend of VCEC may have synergistic effects for protecting endothelial barrier function against oxidative damage, acting via multiple mechanisms of action. However, further research is needed to elucidate the specific compounds that contribute to the synergistic effects on antioxidant activity and endothelial barrier function.

In conclusion, our study has demonstrated for the first time that combining extracts from the leaves of *V. vinifera* and *C. asiatica* had a synergistic effect on protecting the endothelium against oxidative stress. Compared with VE or CE alone, VCEC shows a stronger protective effect on endothelial barrier function owing to its antioxidant activity and regulation of NO and VE-cadherin levels. Therefore, VCEC may potentially be considered a useful therapeutic for the treatment of vascular diseases associated with oxidative stress. However, *in vivo* studies and clinical trials are required to prove the efficacy of VCEC in reducing the risk of vascular diseases.
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![Representative high-performance liquid chromatography chromatogram at 360 nm: standard solutions of (A) quercetin 3-glucuronide, (B) *Vitis vinifera* L. leaf extract, (C) *Centella asiatica* extract, and (D) *V. vinifera* L. leaf and *C. asiatica* extract combination.](PNFS-25-173-f1){#F1}

![Representative high-performance liquid chromatography chromatogram at 205 nm: standard solutions of (A) asiaticoside, (B) *Vitis vinifera* L. leaf extract, (C) *Centella asiatica* extract, and (D) *V. vinifera* L. leaf and *C. asiatica* extract combination.](PNFS-25-173-f2){#F2}

![Antioxidant activity of *Vitis vinifera* L. leaf extract (VE), *Centella asiatica* extract (CE), and *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) in oxygen radical antioxidant capacity (ORAC) assays. The antioxidant activities of VE, CE, or VCEC were evaluated using ORAC assays. Total antioxidant activity is expressed as μM Trolox equivalents (TE)/g. Values are shown as the mean±SD (n=3 with three replicates in each experiment). ^\#\#^*P*\<0.01 compared with the VE or CE group.](PNFS-25-173-f3){#F3}

![Effects of *Vitis vinifera* L. leaf extract (VE), *Centella asiatica* extract (CE), and *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) on the viability of HUVECs. Cells were treated with various concentrations of VE, CE, or VCEC for 24 h. Cell viability was determined by the thiazolyl blue tetrazolium bromide assays. The results are expressed as a percentage of the control. Values are the mean±SD (n=3 with three replicates in each experiment).](PNFS-25-173-f4){#F4}

![Effects of *Vitis vinifera* L. leaf extract (VE), *Centella asiatica* extract (CE), and *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) on the intracellular reactive oxygen species (ROS) production in human umbilical vein endothelial cells in conditions of oxidative stress induced by H~2~O~2~. Cells were treated with various concentrations of VE, CE, and VCEC for 30 min before exposure to 500 μM H~2~O~2~ for 4 h. ROS production was determined using 25 mM of 2',7'-dichlorofluorescein diacetate. The results are expressed as a percentage of the control. Values are shown as the mean±SD (n=3 with three replicates in each experiment). \*\**P*\<0.01 and \*\*\**P*\<0.001 compared with the H~2~O~2~-alone group.](PNFS-25-173-f5){#F5}

![Effects of *Vitis vinifera* L. leaf extract (VE), *Centella asiatica* extract (CE), and *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) on nitric oxide production in human umbilical vein endothelial cells in conditions of oxidative stress induced by H~2~O~2~. Cells were treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, or 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) for 30 min before exposure to 500 μM H~2~O~2~ for 4 h. Total nitrite concentrations in culture supernatants were measured using the Griess reagent. The results are expressed as a percentage of the control. Values are presented as mean±SD (n=3 with three replicates in each experiment). \*\**P*\<0.01 compared with the H~2~O~2~-alone group; ^\#^*P*\<0.05 or ^\#\#^*P*\<0.01 compared with the VE or CE group.](PNFS-25-173-f6){#F6}

![Effects of Vitis vinifera L. leaf extract (VE), Centella asiatica extract (CE), and V. vinifera L. leaf and C. asiatica extract combination (VCEC) on the transendothelial electrical resistance (TEER) of human umbilical vein endothelial cell (HUVEC) monolayers in conditions of oxidative stress induced by H~2~O~2~. Cells were treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, or 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) for 30 min before exposure to 500 μM H~2~O~2~ for 4 h. The TEER of HUVEC monolayers was detected using a Millicell-ERS ohmmeter. Values represent the mean±SD (n=3 with three replicates in each experiment). \*\**P*\<0.01 compared with the H~2~O~2~-alone group; ^\#^*P*\<0.05 or ^\#\#^*P*\<0.01 compared with the VE or CE group.](PNFS-25-173-f7){#F7}

![Effects of *Vitis vinifera* L. leaf extract (VE), *Centella asiatica* extract (CE), and *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) on the monolayer permeability of human umbilical vein endothelial cells in conditions of oxidative stress conditions induced by H~2~O~2~. Cells were treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, or 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) for 30 min before exposure to 500 μM H~2~O~2~ for 4 h. The fluorescent intensities of fluorescein isothiocyanate-dextran in receiver wells were quantified at an excitation/emission wavelength of 485/535 nm. The results are expressed as a percentage of the control. Values are the mean±SD (n=3 with three replicates in each experiment). \*\**P*\<0.01 or \*\*\**P*\<0.001 compared with the H~2~O~2~-alone group; ^\#^*P*\<0.05 or ^\#\#\#^*P*\<0.001 compared with the VE or CE group.](PNFS-25-173-f8){#F8}

![Effects of *Vitis vinifera* L. leaf extract (VE), *Centella asiatica* extract (CE), and *V. vinifera* L. leaf and *C. asiatica* extract combination (VCEC) on vascular endothelial-cadherin (VE-cadherin) expression in human umbilical vein endothelial cells in conditions of oxidative stress induced by H~2~O~2~. Cells were treated with 37.5 μg/mL of VE, 12.5 μg/mL of CE, or 50 μg/mL of VCEC (37.5 μg/mL of VE+12.5 μg/mL of CE) for 30 min before exposure to 500 μM H~2~O~2~ for 4 h. VE-cadherin concentrations were determined with an ELISA. The results are expressed as a percentage of the control. Values are shown as the mean±SD (n=3 with three replicates in each experiment). \**P*\<0.05 or \*\**P*\<0.01 compared with the H~2~O~2~-alone group; ^\#^*P*\<0.05 or ^\#\#^*P*\<0.01 compared with the VE or CE group.](PNFS-25-173-f9){#F9}

###### 

Regression equation, correlation coefficients (*R*^2^), limits of detection, and quantification for high-performance liquid chromatography analysis

  Compound                  Calibration curve equation, *R*^2^   Limit of detection (μg/mL)   Limit of quantification (μg/mL)
  ------------------------- ------------------------------------ ---------------------------- ---------------------------------
  Quercetin 3-glucuronide   *y*=29.19x+15.05, 0.9992             0.19                         0.56
  Asiaticoside              *y*=2.4256x+7.5597, 0.9992           0.39                         1.19

###### 

Contents of quercetin 3-glucuronide and asiaticoside in VCEC (unit: mg/g)

  Content   Compound    
  --------- ----------- -----------
  VE        11.4±0.16   ND
  CE        ND          95.6±0.22
  VCEC      8.5±0.12    24.9±0.17

Data are expressed as mean±SD of three replicate experiments.

ND: not detected.

VE, *Vitis vinifera* L. leaf extract; CE, *Centella asiatica* extract; VCEC, *V. vinifera* L. leaf and *C. asiatica* extract combination.

###### 

Unexpected synergistic effect of *Vitis vinifera* L. and *Centella asiatica* on vascular permeability

  Composition                                Material   Dose (μg/mL)   Percent inhibition
  ------------------------------------------ ---------- -------------- --------------------
  VCEC                                       VE         35.5           60.6 (*x*)
  CE                                         12.5       36.1 (*y*)     
  Expected[1)](#t3f2){ref-type="table-fn"}   50         74.8           
  Observed[2)](#t3f3){ref-type="table-fn"}   50         77.8           

Colby's equation=*x+y−(xy)*/100.

^1)^Calculated value according to Colby's method.

^2)^Data observed when a composition was treated at 50 μg/mL, when observed≥expected=unexpected synergy.

VCEC, *V. vinifera* L. leaf and *C. asiatica* extract combination; VE, *V. vinifera* L. leaf extract; CE, *C. asiatica* extract.
